STOCK TITAN

Prelude Therapeutics Inc - PRLD STOCK NEWS

Welcome to our dedicated news page for Prelude Therapeutics (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Prelude Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Prelude Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.5%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
earnings
Prelude Therapeutics Inc

Nasdaq:PRLD

PRLD Rankings

PRLD Stock Data

260.32M
13.63M
6.92%
73.74%
1.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Wilmington

About PRLD

prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.